# Elevance Health, Inc.: overview

ELV · NYSE · CIK 1156039 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elv.md) · [Financials](/companies/elv/financials.md) · [Filings](/companies/elv/filings.md) · [Insiders](/companies/elv/insiders.md)

Latest reported revenue: [$51.43bn](/filings/0001156039-26-000071.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 21, 2026 (XBRL us-gaap:Revenues, accession 0001156039-26-000071).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [45.4 d](/filings/0001156039-26-000013.md) | [48.9](/filings/0001156039-26-000043.md) | [49.8](/filings/0001156039-26-000060.md) | [50.7](/filings/0001156039-26-000071.md) | [49.7 d](/filings/0001156039-26-000013.md) | [50.2](/filings/0001156039-26-000043.md) | [50.5](/filings/0001156039-26-000060.md) | [51.4](/filings/0001156039-26-000071.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [1.5% d](/filings/0001156039-26-000013.md) | [6.5%](/filings/0001156039-26-000043.md) | [4.9%](/filings/0001156039-26-000060.md) | [2.6%](/filings/0001156039-26-000071.md) | [0.6% d](/filings/0001156039-26-000013.md) | [4.2%](/filings/0001156039-26-000043.md) | [3.5%](/filings/0001156039-26-000060.md) | [2.5%](/filings/0001156039-26-000071.md) |
| Net margin | % | [0.9% d](/filings/0001156039-26-000013.md) | [4.5%](/filings/0001156039-26-000043.md) | [3.5%](/filings/0001156039-26-000060.md) | [2.3%](/filings/0001156039-26-000071.md) | [1.1% d](/filings/0001156039-26-000013.md) | [3.5%](/filings/0001156039-26-000043.md) | [2.9%](/filings/0001156039-26-000060.md) | [2.7%](/filings/0001156039-26-000071.md) |
| Diluted EPS | $ per share | not reported | [9.61](/filings/0001156039-26-000043.md) | [7.72](/filings/0001156039-26-000060.md) | [5.32](/filings/0001156039-26-000071.md) | not reported | [8.00](/filings/0001156039-26-000043.md) | [6.71](/filings/0001156039-26-000060.md) | [6.27](/filings/0001156039-26-000071.md) |
| Free cash flow | $bn | [0.4 d](/filings/0001156039-26-000013.md) | [0.8](/filings/0001156039-26-000043.md) | [1.8 d](/filings/0001156039-26-000060.md) | [0.8 d](/filings/0001156039-26-000071.md) | [(0.2) d](/filings/0001156039-26-000013.md) | [4.1](/filings/0001156039-26-000043.md) | [1.6 d](/filings/0001156039-26-000060.md) | [1.0 d](/filings/0001156039-26-000071.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [139](/filings/0001156039-24-000015.md) | [157](/filings/0001156039-25-000010.md) | [171](/filings/0001156039-26-000013.md) | [177](/filings/0001156039-26-000013.md) | [199](/filings/0001156039-26-000013.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [5.5%](/filings/0001156039-24-000015.md) | [5.3%](/filings/0001156039-25-000010.md) | [5.0%](/filings/0001156039-26-000013.md) | [4.4%](/filings/0001156039-26-000013.md) | [3.6%](/filings/0001156039-26-000013.md) |
| Net margin | % | [4.4%](/filings/0001156039-24-000015.md) | [3.8%](/filings/0001156039-25-000010.md) | [3.5%](/filings/0001156039-26-000013.md) | [3.4%](/filings/0001156039-26-000013.md) | [2.8%](/filings/0001156039-26-000013.md) |
| Diluted EPS | $ per share | [24.95](/filings/0001156039-24-000015.md) | [24.28](/filings/0001156039-25-000010.md) | [25.22](/filings/0001156039-26-000013.md) | [25.68](/filings/0001156039-26-000013.md) | [25.21](/filings/0001156039-26-000013.md) |
| Free cash flow | $bn | [7.3](/filings/0001156039-24-000015.md) | [7.2](/filings/0001156039-25-000010.md) | [6.8](/filings/0001156039-26-000013.md) | [4.6](/filings/0001156039-26-000013.md) | [3.2](/filings/0001156039-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/elv/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 273 | $447.19 | $122.1k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 827 | $446.05 | $368.9k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 160 | $444.85 | $71.2k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 440 | $443.81 | $195.3k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 480 | $442.61 | $212.5k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 2,343 | $441.34 | $1.0m | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 1,720 | $440.44 | $757.6k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 1,160 | $439.25 | $509.5k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 240 | $438.22 | $105.2k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 560 | $437.07 | $244.8k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 1,660 | $436.20 | $724.1k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 321 | $435.25 | $139.7k | [Form 4](/filings/0001748691-26-000008.md) |
| 2026-10-22 | [Kaye Mark](/insiders/1748691.md) | EVP & CFO, Officer | Sale (S) | 400 | $434.00 | $173.6k | [Form 4](/filings/0001748691-26-000008.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $7.34bn | 18,991,090 |  | Reduced −896,021 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.44bn | 14,058,204 |  | Reduced −287,255 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $4.03bn | 10,426,610 |  | Added +137,914 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $3.56bn | 9,213,513 |  | Added +984,976 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.40bn | 6,214,356 |  | Reduced −141,721 |
| [Sanders Capital, LLC](/funds/1508097.md) | 2026-06-30 | $2.25bn | 5,825,024 |  | Reduced −69,279 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.99bn | 5,166,124 |  | Reduced −26,583 |
| [HARRIS ASSOCIATES L P](/funds/813917.md) | 2026-06-30 | $1.90bn | 4,924,511 |  | Added +127,985 |
| [Artisan Partners Limited Partnership](/funds/1466153.md) | 2026-06-30 | $1.77bn | 4,581,222 |  | Reduced −545,953 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $1.64bn | 4,234,231 |  | Reduced −583,179 |

## Recent filings

[All 1,507 filings](/companies/elv/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-21 | 18:14 ET | [10-Q](/filings/0001156039-26-000071.md) | Quarterly report, period 2026-09-30 | 0001156039-26-000071 |
| 2026-10-21 | 10:01 ET | [8-K](/filings/0001156039-26-000068.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001156039-26-000068 |
| 2026-09-10 | 10:00 ET | [8-K](/filings/0001156039-26-000063.md) | 7.01 Regulation FD disclosure | 0001156039-26-000063 |
| 2026-07-15 | 15:27 ET | [10-Q](/filings/0001156039-26-000060.md) | Quarterly report, period 2026-06-30 | 0001156039-26-000060 |
| 2026-07-15 | 10:01 ET | [8-K](/filings/0001156039-26-000058.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001156039-26-000058 |
| 2026-06-10 | 10:01 ET | [8-K](/filings/0001156039-26-000049.md) | 7.01 Regulation FD disclosure | 0001156039-26-000049 |
| 2026-05-13 | 20:07 ET | [8-K](/filings/0001156039-26-000046.md) | 5.07 Shareholder vote results | 0001156039-26-000046 |
| 2026-04-22 | 14:09 ET | [10-Q](/filings/0001156039-26-000043.md) | Quarterly report, period 2026-03-31 | 0001156039-26-000043 |
| 2026-04-22 | 10:02 ET | [8-K](/filings/0001156039-26-000039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001156039-26-000039 |
| 2026-03-27 | 20:21 ET | [DEF 14A](/filings/0001156039-26-000031.md) | Proxy statement, period 2026-05-13 | 0001156039-26-000031 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001156039-26-000013.md), filed Feb 6, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1156039
- Tickers: ELV
- Exchange: NYSE
- SIC code: 6324 Hospital & Medical Service Plans
- State of incorporation: IN
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.